Fig. 3

Effect of Andro on COX-2 expression in human breast cancer cells. The expression level of COX-2 protein was analyzed by Western blot in human breast cancer cells treated without a Andro treatment. b Expression levels of COX-2 protein and gene were analyzed by Western blotting (upper) and RT-PCR (bottom) in MDA-MB-231 cells treated with indicated doses of Andro for 48 h. c MDA-MB-231cells were cotransfected with pNFκB-luc with Renilla luciferase reporter (as internal control) for 24 h and then treated with Andro or CB for 48 h. Luciferase activity was determined using a dual-luciferase reporter assay system. d MDA-MB-231cells cells were treated with indicated doses of Andro for 48 h after pretreatment with the COX-2 selective inhibitor Celecoxib (40 μM) for 8 h, and the cell viability was determined by CCK-8 assay. Data were represented as the mean ± S.D. of at least three independent experiments. (*P < 0.05, **P < 0.01, Andro treatment vs vehicle control groups)